Merck & Co to spin off cancer unit ahead of Keytruda patent cliff

2026-03-08 05:03:51

Merck & Co. is reportedly planning to spin off its oncology division to safeguard its broader healthcare business from the upcoming patent cliff of its blockbuster drug, Keytruda, in 2028. This strategic move aims to diversify the company as generic versions of Keytruda, which generated a significant portion of Merck’s 2025 revenue, are expected to enter the market. The new cancer business will be led by company executive Jannie Ossthuizien.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.